The KRAS-mutant rectal cancer organoids showed resistance to the EGFR inhibitor cetuximab, whereas KRAS-wild-type tumoroids displayed sensitivity to this drug, consistent with the clinical trial showing that the KRAS mutation correlates with resistance to EGFR-targeted therapy [107]. The gene discussed is KRAS; the disease is rectal cancer.